2021-04-23 06:15Pressmeddelande

Global turnout for instant business and knowledge-sharing at NLSDays Digital 2021

Image from the opening sessionImage from the opening session

SwedenBIO announced record figures for the eighth NLSDays event, which moved to an entirely digital format this week and also provided the first NLSInvest day at the start of the program.

The event brought together a global community of life science leaders, from big pharma to dynamic tech companies, as well as a record number of investors, and experts from academic, clinical and regulatory institutions. The event focused on creating partnerships to accelerate advancements in healthcare technologies that will benefit patients globally as well as promote industry growth. 

On April 19th, the inaugural Nordic Life Science investment day (NLSInvest) was held, featuring 80 selected Rising Stars who were given the opportunity to pitch to investors in three dedicated tracks: biotech/pharma, medtech/diagnostics and digital/e-health. The winners from each track received cash prizes and complimentary registrations to NLSDays 2022.

The main NLSDays Digital program was held from April 20th-21st, and the virtual format encouraged greater global participation than ever, with over 800 participants joining from more than 30 countries. Of these, 21% attendees were investors from 115 financing companies (including venture capital, family offices and business angels). Networking and partnering continued strongly through the week, with a record number (over 9600) of meeting requests made among delegates, of which at least 1700 were accepted and scheduled.

The full program included more than 200 speakers across the six supersessions, workshops and company presentations. Several common themes emerged during the week, in particular collaboration, sustainability and innovation. A recurring question was that of how life scientists across the Nordic ecosystem should continue working together to bridge gaps, in order to ensure that urgently-needed new technologies and therapies are delivered to market. Topics included funding; the genetics and translational challenges of the microbiome; novel vaccine technologies; bioconvergence; precision medicine; digital therapies and the challenges of adapting regulations to suit new medtech devices. 

Helena Strigård, Director General of SwedenBIO, comments: “NLSDays Digital meant everything was instant – from instant connections, to instant business and real outcomes. This was supported by the high levels of interactivity during the event, and increased rates of investor and partnering meetings compared with previous years.

“We were delighted by the warm welcome we received and the really positive feedback from our delegates throughout the week,” Helena adds.

NLSDays in brief (figures so far):

800+ delegates from over 30 countries
170 investors representing 115 investing companies
9600+ meeting requests, 1700+ accepted/scheduled
200+ speakers and presenters
50+ digital exhibitors
40+ sponsors

Returning to Malmö next year!

NLSDays will return to MalmöMässan, Sweden, next year. Join us from 20-21 April 2022. 

About NLSDays

NLSDays is a SwedenBIO event. It was founded in 2013 and has grown rapidly to become the largest Nordic partnering conference for the global life science industry.

Among the Big Pharma, investors and other major players registered for the event so far are Cytiva, AstraZeneca, Nordic Innovation, Hadean Ventures, NDA Group, Almi Invest, DNB, Elypta, Novo Nordisk, Omega Funds, MSD, Seventure Partners, BioGaia, Cellink, Johnson & Johnson Innovation, and much more.




Olivier DuChamp
Managing Director, NLSDays

+33 (0) 608 80 45 15

Editorial enquiries

Kate Whelan
Notch Communications

+46 (0) 702 381 149

Om SwedenBIO

SwedenBIO is the founder and organizer of Nordic Life Science Days. The nearly 300 members operate across all sub-sectors from pharmaceutical, biotechnology, medical technology to diagnostics. SwedenBIO serves to the benefit of the entire life science industry in Sweden and is a member-driven, private, non-profit organization. The main objective is to improve the conditions for the life science industry for the benefit of industry growth and business development.